Patents by Inventor Steffen Walter
Steffen Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975042Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: July 23, 2021Date of Patent: May 7, 2024Assignee: Immatics Biotechnologies GmbHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11969455Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: June 25, 2021Date of Patent: April 30, 2024Assignee: Immatics Biotechnologies GmbHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11957730Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: July 23, 2021Date of Patent: April 16, 2024Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES
Publication number: 20240115609Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of ?? T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of ?? T cells while depleting ?- and/or ?-TCR positive cells. T cell populations comprising expanded ?? T cell and depleted or reduced ?- and/or ?-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.Type: ApplicationFiled: May 18, 2023Publication date: April 11, 2024Inventors: Monique DAO, Steffen WALTER, Melinda MATA, Aleksandra NORWICKA, Yannick BULLIARD, Sarah MISSELL, Sabrina KUTTRUFF-COQUI, Norbert HILF -
Patent number: 11939376Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: August 21, 2020Date of Patent: March 26, 2024Assignee: Immatics Biotechnology GmbHInventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
-
Patent number: 11939400Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 10, 2022Date of Patent: March 26, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11939401Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 18, 2022Date of Patent: March 26, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11890334Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 30, 2021Date of Patent: February 6, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
-
Patent number: 11890333Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 30, 2021Date of Patent: February 6, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
-
Patent number: 11883462Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: May 14, 2021Date of Patent: January 30, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Publication number: 20240024929Abstract: A method of keeping a viewing area through a transparent element (10) of an optical monitoring device (100) clear, comprising the steps of: Forming a closed film (50) of a liquid on the transparent element (10); Coupling ultrasonic waves (64) into the transparent element (10), wherein loosening of contaminations (70) and/or adhesions to the transparent element (10) is promoted by the ultrasonic waves (64) coupled into the liquid film (50) and/or the transparent element (10).Type: ApplicationFiled: September 17, 2021Publication date: January 25, 2024Applicant: EchoVista GmbHInventors: Mincheol SHIN, Oliver Simon MATTHEWS, Steffen WALTER
-
Patent number: 11866517Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: November 12, 2021Date of Patent: January 9, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11859017Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 18, 2022Date of Patent: January 2, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11851673Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: GrantFiled: March 10, 2021Date of Patent: December 26, 2023Assignee: Immatics US, Inc.Inventors: Melinda Mata, Mamta Kalra, Yannick Bulliard, Steffen Walter, Ali Mohamed
-
Patent number: 11850274Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: April 23, 2021Date of Patent: December 26, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11839643Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: May 21, 2021Date of Patent: December 12, 2023Assignee: Immatics Biotechnologies GmbHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 11820337Abstract: An optical monitoring system serves to monitor surroundings, having a monitoring apparatus, the visual or scanning field of which is captured by a lens, and a protection panel (112) which protects the lens from precipitation and covers at least the visual or scanning field of the monitoring apparatus. In order to avoid the signal quality of the monitoring apparatus being impaired by precipitation on the protection panel, it is proposed that the protection panel (12; 112; 218; 318) is acoustically coupled to at least one ultrasonic transducer (10). The optical monitoring system can be included into the control system of a vehicle for autonomous driving, wherein, overall, it is possible to obtain increased safety of the control system.Type: GrantFiled: September 14, 2018Date of Patent: November 21, 2023Assignee: EchoVista GmbHInventors: Lars Najorka, Steffen Walter, Ole Gustav Johannessen, Oliver Simon Matthews, Mincheol Shin
-
Patent number: 11814446Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: April 23, 2021Date of Patent: November 14, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Publication number: 20230356696Abstract: An optical monitoring system serves to monitor surroundings, having a monitoring apparatus, the visual or scanning field of which is captured by a lens, and a protection panel (112) which protects the lens from precipitation and covers at least the visual or scanning field of the monitoring apparatus. In order to avoid the signal quality of the monitoring apparatus being impaired by precipitation on the protection panel, it is proposed that the protection panel (12; 112; 218; 318) is acoustically coupled to at least one ultrasonic transducer (10). The optical monitoring system can be included into the control system of a vehicle for autonomous driving, wherein, overall, it is possible to obtain increased safety of the control system.Type: ApplicationFiled: May 8, 2023Publication date: November 9, 2023Applicant: EchoVista GmbHInventors: Lars NAJORKA, Steffen WALTER, Ole Gustav JOHANNESSEN, Oliver Simon MATTHEWS, Mincheol SHIN
-
Patent number: 11759507Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: June 28, 2022Date of Patent: September 19, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh